Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed for type 2 diabetes management and now widely prescribed for chronic weight management. It is the active compound in brand-name medications Ozempic, Wegovy, and Rybelsus.
Semaglutide mimics the natural GLP-1 hormone released after meals, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and signaling fullness to the brain. These combined effects dramatically reduce caloric intake and regulate blood sugar, producing significant and sustained weight loss.
Clinical trials show average weight loss of 15–17% of body weight over 68 weeks. Compounded semaglutide through telehealth providers offers significant cost savings vs brand-name versions. Most users experience noticeable appetite suppression within the first 1–2 weeks.